Markets

Health Care Sector Update for 09/25/2015: NAVB, BIIB, AMGN

Top Health-care stocks:

JNJ: +1.3%

PFE: +1.9%

ABT: flat

MRK: +1.2%

AMGN: +0.9%

Health-care shares were mainly higher in pre-market trade Friday.

In health-care stocks news, Navidea Biopharmaceuticals ( NAVB ) reported Friday morning its Macrophage Therapeutics unit developed the first two therapeutic Manocept immunoconstructs, MT-1001 and MT-2001, designed to target and kill activated CD206+ macrophages. Macrophages are cells of the immune system.

Shares in the company were unchanged at $2.40 pre-bell. Over the past 52 weeks, the company has traded between $0.97 and $2.50.

Biopharmaceutical company Biogen Idec ( BIIB ) said it has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for the marketing authorization of ELOCTA in the treatment of hemophilia A.

If approved it will be the first hemophilia A treatment with prolonged circulation available in the European Union.

Shares in the company were 2.0% higher at $299 pre-bell. This remains towards the lower end of the company's 52 week trading range.

And Amgen ( AMGN ) shares were 0.9% higher at $144.77 pre-market after the company said it received a positive opinion from the Committee for Medicinal Products for Human Use ( CHMP ) recommending marketing authorization for two of its drugs.

The company's 52 week trading range is between $127.67 and $181.81.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NAVB CHMP BIIB AMGN

Other Topics

Commodities

Latest Markets Videos

    MTNewswires

    Founded in 1999, MT Newswires (formerly known as Midnight Trader) is a leading provider of original source, multi-asset class, real-time, global financial news and information to most of the largest banks, brokerage firms and professional market data, trading & research applications in North America.

    Learn More